These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
405 related articles for article (PubMed ID: 28625622)
1. PD-L1 expression in neuroendocrine tumors of the lung. Tsuruoka K; Horinouchi H; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Asakura K; Nakagawa K; Sakurai H; Watanabe SI; Tsuta K; Ohe Y Lung Cancer; 2017 Jun; 108():115-120. PubMed ID: 28625622 [TBL] [Abstract][Full Text] [Related]
2. Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor. Inamura K; Yokouchi Y; Kobayashi M; Ninomiya H; Sakakibara R; Nishio M; Okumura S; Ishikawa Y Cancer Med; 2017 Oct; 6(10):2347-2356. PubMed ID: 28925087 [TBL] [Abstract][Full Text] [Related]
3. PD-L1 Expression in Small Cell and Large Cell Neuroendocrine Carcinomas of Lung: an Immunohistochemical Study with Review of Literature. Guleria P; Kumar S; Malik PS; Jain D Pathol Oncol Res; 2020 Oct; 26(4):2363-2370. PubMed ID: 32506394 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors. Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013 [TBL] [Abstract][Full Text] [Related]
5. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194 [TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression in large cell neuroendocrine carcinoma of the lung. Eichhorn F; Harms A; Warth A; Muley T; Winter H; Eichhorn ME Lung Cancer; 2018 Apr; 118():76-82. PubMed ID: 29572007 [TBL] [Abstract][Full Text] [Related]
7. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; Stallinga CM; Roemen GM; Speel EJM; Dingemans AC; Lung Cancer; 2019 Apr; 130():179-186. PubMed ID: 30885341 [TBL] [Abstract][Full Text] [Related]
8. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509 [TBL] [Abstract][Full Text] [Related]
9. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma. Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003 [TBL] [Abstract][Full Text] [Related]
10. Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation. von Hardenberg J; Hartmann S; Nitschke K; Worst TS; Ting S; Reis H; Nuhn P; Weis CA; Erben P Clin Genitourin Cancer; 2019 Apr; 17(2):145-153.e5. PubMed ID: 30709785 [TBL] [Abstract][Full Text] [Related]
11. Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung. Kim HS; Lee JH; Nam SJ; Ock CY; Moon JW; Yoo CW; Lee GK; Han JY J Thorac Oncol; 2018 May; 13(5):636-648. PubMed ID: 29378266 [TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data. Dix Junqueira Pinto G; de Souza Viana L; Scapulatempo Neto C; Vicente Serrano S J Immunol Res; 2016; 2016():9839685. PubMed ID: 27747247 [TBL] [Abstract][Full Text] [Related]
14. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506 [TBL] [Abstract][Full Text] [Related]
16. hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors. Ye B; Cappel J; Findeis-Hosey J; McMahon L; Yang Q; Xiao GQ; Xu H; Li F Hum Pathol; 2016 Feb; 48():142-7. PubMed ID: 26596584 [TBL] [Abstract][Full Text] [Related]
17. PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. Yu H; Batenchuk C; Badzio A; Boyle TA; Czapiewski P; Chan DC; Lu X; Gao D; Ellison K; Kowalewski AA; Rivard CJ; Dziadziuszko R; Zhou C; Hussein M; Richards D; Wilks S; Monte M; Edenfield W; Goldschmidt J; Page R; Ulrich B; Waterhouse D; Close S; Jassem J; Kulig K; Hirsch FR J Thorac Oncol; 2017 Jan; 12(1):110-120. PubMed ID: 27639678 [TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine tumors of the lung: A five-year retrospective experience of Egyptian NCI (2010-2014). Saber M; Ismail Y; Alieldin N; Loay I; El Zawahry M J Egypt Natl Canc Inst; 2018 Dec; 30(4):151-158. PubMed ID: 30470605 [TBL] [Abstract][Full Text] [Related]